{
  "pmid": "37176780",
  "topic": "sepsis_treatment_plan",
  "pdf_path": "Annane_Sepsis_Corpus\\papers\\PMID_37176780\\paper.pdf",
  "sectionizer": "simple_pdfplumber",
  "sections": {
    "Abstract": "Journal of Clinical Medicine Review Corticosteroids in ARDS EmmanuelleKuperminc1,NicholasHeming1,2,3,MiguelCarlos1andDjillaliAnnane1,2,3,* 1 DepartmentofIntensiveCare,HôpitalRaymondPoincaré,APHPUniversityVersaillesSaint Quentin-UniversityParisSaclay,92380Garches,France 2 LaboratoryofInfection&Inflammation—U1173,SchoolofMedicineSimoneVeil,UniversityVersaillesSaint Quentin-UniversityParisSaclay,INSERM,92380Garches,France 3 FHUSEPSIS(SaclayandParisSeineNordEndeavourtoPerSonalizeInterventionsforSepsis), 92380Garches,France * Correspondence:djillali.annane@aphp.fr Abstract:Acuterespiratorydistresssyndrome(ARDS)isfrequentlyassociatedwithsepsis.ARDS andsepsisexhibitacommonpathobiology, namelyexcessiveinflammation. Corticosteroidsare powerfulanti-inflammatoryagentsthatareroutinelyusedinsepticshockandinoxygen-dependent SARS-CoV-2relatedacuterespiratoryfailure.Recently,corticosteroidswerefoundtoreducemortality inseverecommunity-acquiredpneumonia. Corticosteroidsmaythereforealsohavearoletoplay inthetreatmentofARDS.ThisnarrativereviewwasundertakenfollowingaPubMedsearchfor EnglishlanguagereportspublishedbeforeJanuary2023usingthetermsacuterespiratorydistress syndrome,sepsisandsteroids.Additionalreportswereidentifiedbyexaminingthereferencelistsof selectedarticlesandbasedonpersonnelknowledgeoftheauthorsofthefield.High-qualityresearch isneededtofullyunderstandtheroleofcorticosteroidsinthetreatmentofARDSandtodetermine theoptimaltiming,dosinganddurationoftreatment. Keywords:glucocorticoids;acuterespiratorydistresssyndrome;sepsis 1. Introduction 1.1. Sepsis—Definition,EpidemiologyandPathophysiology Citation:Kuperminc,E.;Heming,N.; Sepsisisdefinedasa“life-threateningorgandysfunctioncausedbyadysregulated Carlos,M.;Annane,D. hostresponsetoinfection”[1]. Theabnormalimmuneresponsecausessystemicinflam- CorticosteroidsinARDS.J.Clin.Med. mationandorgandysfunction[2]. Sepsisisaglobalcauseofmorbidityandmortality[3]. 2023,12,3340. https://doi.org/ Globally,theincidenceofsepsisisestimatedat190/100,000person-years,andmortality 10.3390/jcm12093340 isbetween20and30%[4]. Themostcommoncausesofsepsisarediarrhealdisease,with 9.2millionannualscasesglobally,whilethemostcommoncauseofsepsis-relateddeathis AcademicEditors:JesúsVillarand lowerrespiratorytractinfections,with1.8millionannualscasesglobally[5]. Sepsiswas WilliamE.Hurford recentlyidentifiedasaglobalhealthprioritybytheWorldHealthOrganization[6]. The Received:23March2023 annualcostofsepsisintheUSisover$20billion[7]. Halfofsepsissurvivorsexperience Revised:4May2023 subsequentphysicalandpsychologicaldisabilities,significantlyalteringtheirqualityof Accepted:5May2023 life[8]. Published:8May2023 Thepathobiologyofsepsisiscomplex,associatingimmune,hormonal,energeticand metabolicanomalies. Theexcessiveinflammatoryresponseobservedinsepsisiscausedby animbalancebetweentwodistinctpathways,ontheonehandtheactivatedinflammatory pathway,(NF-kBsignalingsystem),andontheotherhandthedysregulatedhypothalamic- Copyright: © 2023 by the authors. pituitary-adrenal-axis(HPA)response[9]. Theinitialhostresponsefollowinganinsult Licensee MDPI, Basel, Switzerland. involvesrecognitionofdangersignalsbyinnateimmunecellsleadingtotheactivation This article is an open access article ofmultipleandsometimesredundantsignalingpathways. Theinitialinflammatoryre- distributed under the terms and sponse is triggered by the interaction between pathogen-associated molecular patterns conditionsoftheCreativeCommons Attribution(CCBY)license(https:// (PAMPs)andpattern-recognitionreceptorsonhostimmunecells. Thesereceptorsinclude creativecommons.org/licenses/by/ severalfamiliesofimmunereceptorsuchasToll-likereceptors(TLR),C-typelectinrecep- 4.0/). tors,retinoicacidinduciblegene1-likereceptors,andnucleotide-bindingoligomerization J.Clin.Med.2023,12,3340.https://doi.org/10.3390/jcm12093340 https://www.mdpi.com/journal/jcm J.Clin.Med.2023,12,3340 2of16 domain-likereceptors(NOD-likereceptors),localizedoncellmembranes,inendosomes, orinthecytoplasm[10]. Excessiveinflammationmayleadtotissuedamageandcelldeath, causingthereleaseofadditionaldangermolecules(damage-associatedmolecularpatterns; DAMPs),suchastheS100protein,highmobilitygroupbox1,extracellularRNA,DNA andhistoneswhichcanfurthercontributetoinflammationthroughactivationofadditional pattern-recognitionreceptors[11]. BindingofaligandtoaToll-likereceptorleadstothe activationofsignalingpathwaysimplicatingNF-κB.Whenactivated,NF-κBtrafficsfrom thecytoplasmtothenucleusandbindstotranscriptionsites,activatinggenesinvolvedin theinflammatoryresponse. Implicatedgenesincludegenestranscribingpro-inflammatory cytokines[tumornecrosisfactoralpha[TNFa]andinterleukin-1[IL-1]),chemokines(inter- cellularadhesionmolecule-1[ICAM-1]andvascularcelladhesionmolecule-1[VCAM-1]), andpathwaysregulatingtheproductionofnitricoxide. Theimmuneresponseisinitially mediatedbycellsoftheinnateimmunesystem,followedbytheadaptiveimmunesystem. Bothpro-inflammatoryandanti-inflammatoryresponsesareinvolved[12]. Thebalance betweenproandanti-inflammatorymediatorsregulatestheinflammatoryprocess[13,14]. Asinflammationprogresses,additionalorgansmaybeaffected,suchasthecardiovascu- lar,renal,orneurologicalsystems. Coagulationabnormalitiesmayalsooccur,leadingto disseminatedintravascularcoagulation,therebypromotingadditionaltissuedamage[15]. Respiratoryinvolvementmayalsooccurduringsepsis,leadingtoacuterespiratorydistress syndrome,evenwhenpneumoniaisnottheinitialtriggerofsepsis. Theendocrineresponsetostressinvolvesstresshormones,notablyglucocorticoids (cortisol),whosemainpurposeistomaintainhomeostasisthroughouttheorganismbyop- timizingtheproductionofenergy[16]. Duringstress,thehypothalamic-pituitary-adrenal axisincreasescortisolproductionthroughincreasedproductionofCRH/ACTH[9]. Three keypathophysiologicfeaturesoccursimultaneouslyduringcriticalillness: dysregulation oftheHPAaxis(duetohighlevelofpro-inflammatorycytokines[17]),alteredcortisolsyn- thesisateverystage(alteredCRH/ACTHsynthesis,alteredadrenalsteroidogenesis[18]) andalteredperipheralmetabolismofcortisolandtissueresistancetocorticosteroids[19]. 1.2.AcuteRespiratoryDistressSyndrome[ARDS]—Definition,EpidemiologyandPathophysiology Acute respiratory distress syndrome, or ARDS, is defined by an acute onset of symptoms, bilateral radiographic opacities not fully explained by effusion, atelectasis or masses, and arterial hypoxemia by PaO /FiO < 300 mm Hg (defined as mild if 2 2 200<PaO /FiO ≤300onCPAPorPEEP≥5cmH O;Moderateif100<PaO /FiO ≤200 2 2 2 2 2 onPEEP≥5cmH O;Severeif100≤PaO /onPEEP≥5cmH O],withnocardiogenic 2 2 2 explanation)[20]. TheincidenceofARDSintheUSrangesfrom64.2to78.9cases/100,000 person-years [21]. Mortality associated with ARDS is estimated to be 27–37% [22]. A significantnumberofARDSsurvivorsexperiencefunctionallimitations,suchasmuscle weakness,respiratorysymptoms,anxiety,depressionandcognitiveimpairment[23,24]. Furthermore,longtermmortalityremainssignificantinARDSsurvivors,withmortality ratesof20–34%at5years[23]. Local injury such as caused by pneumonia is the most common cause of ARDS, howeveranysystemicinsult(Transfusion-relatedacutelunginjury,severetraumaticinjury, pancreatitis, etc.] may result in ARDS. Sepsis is one of the main risk factors of ARDS. IntheLUNG-SAFEcohort, pneumoniawasthecauseof59.4%ofcasesofARDSwhile extrapulmonarysepsiswasthecauseof16%ofcasesofARDS[25].SARS-CoV-2pneumonia isanotherwelldocumentedcauseofARDS[25,26]. LunginvolvementinearlyARDSischaracterizedbydiffusealveolardamage,caused bypro-inflammatorymediators(suchasTNF,IL1,IL6,IL8)[27]leadingtotherecruitment andactivationofPMNs,whichinturnreleasetoxicmediators(reactiveoxygenspecies andprotease)[28]. Thisinflammatoryprocessdisruptsalveolarepithelium,altersbasal membranes,impairsfluidresorptionandpromotestheaccumulationinthealveolarspace of proteins and blood cells [29], leading to surfactant inactivation, atelectasis, reduced aeratedlungvolume,intrapulmonaryshuntandrefractoryhypoxemia[30]. ARDSsub- J.Clin.Med.2023,12,3340 3of16 groupswererecentlydescribed. OneARDSsubgroupexhibitsincreasedinflammatory parameters,higherrequirementsofvasopressorsaswellashighermortalityandfewerdays alivefreefrommechanicalventilationororganfailurefree[31]. Theadministrationofanti- inflammatoryagentssuchascorticosteroids,particularlyinthisinflammatorysubgroupof ARDSmaybeofparticularinterest. 1.3. Corticosteroids Corticosteroids are anti-inflammatory agents implicated in several biological pro- cesses,includingcarbohydrate,proteinandlipidmetabolism,andhydro-electrolyticbal- ance. Cortisol(alsoknownashydrocortisone),themainnaturalglucocorticoidinmanis producedbytheadrenalglands. Cortisolisconvertedintocortisone,mainlybythekidney. Corticosteroidmetabolismisregulatedbythehypothalamic-pituitary-adrenalaxis,more specificallybytheadrenocorticotropichormone(ACTH),whichinturnisunderthecontrol ofthecorticotrophin-releasinghormone(CRH).Syntheticcorticosteroidshavebeeninuse for several decades, mainly as powerful anti-inflammatory agents. Knowledge regard- ingtheirbiologicaleffectsderivesfromtheworkofKendall,ReichsteinandHench[32]. Corticosteroidsaredistinguishedbytheirglucocorticoid(anti-inflammatory)andmineralo- corticoideffect[33]. Cellulareffectsofcorticosteroidsaremediatedbybothgenomicand non-genomicsignalingpathways[34]. Thegenomicpathwayinvolvescortisolbindingthe glucocorticoidreceptor(GR),translocationintothecytosol,whereitregulates,bothdirectly orindirectlytheexpressionoftargetgenes[35]. Themaineffectofglucocorticoidsisto inhibittheexpressionofpro-inflammatorycytokines,notablythroughthesequestrationof NF-κB[36]. Glucocorticoidsalsoinhibittheproductionofchemokines(suchasintercellular adhesionmolecule-1[ICAM-1]andvascularcelladhesionmolecule-1[VCAM-1])[37]. Preclinicalstudieshaveshownthattheexpressionoftheglucocorticoidreceptoris increasedinLPSstimulatedmacrophages[38].Deletionoftheglucocorticoidreceptorleads togreatermortalityinanimalmodelsofsepsis[39,40].Theadministrationofcorticosteroids decreasesthelevelofpro-inflammatorycytokines(TNF-α,IL1andIL6)[41]andimproves survival,inratandcaninemodelsofsepsis[42,43]. Humanstudieshaveproducedsimilar results. InhealthyvolunteerschallengedbyLPS,theadministrationofcorticosteroidsre- ducesplasmalevelsofTNF-α[44],IL1andIL6[45].Insepticshocklowdosecorticosteroids led to improved outcomes in recent large scale trials [46–49]. In a multicenter placebo- controlledtrialof1241patientswithsepticshock(APROCCHSS),corticosteroidsreduced theriskof90-daymortality(43%vs. 49.1%,RR0.88(95%CI[0.78–0.99]p=0.03))[48]. In theADRENALplacebo-controlledtrialin3658patientswithsepticshock,corticosteroids didnotreduce90-daymortality(OR0.95,95%CI[0.82–1.10],p=0.5)[50]. Maindifferences between these two trials included sicker",
    "Method": "patients at the time of enrollment in APROC- CHSScomparedtoADRENAL,differentsourcesofsepsis(abdominalinADRENALvs. lung infections in APROCCHSS) and differences in the type of experimental treatment (continuousadministrationofhydrocortisoneinADRENALvs. bolusadministrationof hydrocortisoneinAPROCCHSS;useofhydrocortisoneinADRENALvs. combinationof hydrocortisoneandfludrocortisoneinAPROCCHSS).Subsequentmeta-analysisof61trials showedthatcorticosteroidsimprovedshockreversal,reduced28-daymortality(RR0.91 95% CI [0.84–0.99]) and hospital mortality (RR 0.90, 95% CI [0.82 to 0.99]) but not long termmortality(RR0.97,95%CI[0.91to1.03])[51,52]. Accordingly,thelatestsurviving sepsisguidelinesrecommendedusingcorticosteroidsinadultsepticshockwithanongoing requirementofvasopressors[53]. Arecentmulticenterplacebo-controlledtrialfoundthat corticosteroidsreduce28-daymortalityby−5.6percentagepoints(95%CI,−9.6to−1.7; p=0.006)in795patientswithseverecommunity-acquiredpneumonia[54]. 2. CorticosteroidsinARDS TheefficacyofcorticosteroidsinARDShasbeenasubjectofcontroversyfordecades[55,56]. InanimalmodelsofARDS,corticosteroidsdecreasedtheexpressionofpro-inflammatory mediatorsinlungtissue,includingTNF-a,IL-1a,IL-1b,IL-6andIL-12p40,andreduceslung J.Clin.Med.2023,12,3340 4of16 injurythroughthereductionofoxygenradicalsproducedbyneutrophils[57,58]. Beyond their anti-inflammatory effects during the acute phase of inflammation, corticosteroids also contributed to the resolution of inflammation, trough reprogramming effects on macrophages. CorticosteroidshavebeenadministeredduringtwodistinctphasesofARDS, during the early stage of ARDS when inflammation is expected to be most important and during late phase of ARDS, when lung fibrosis predominates. The biological and pathological characteristics of these two entities differ greatly, explaining the observed conflictingresultsintheeffectsofcorticosteroidsinthesetwodistinctconditions[59]. 2.1. CorticosteroidsinEarlyStageARDS[Table1] The early phase of ARDS is characterized by major alveolar inflammation. Thus, corticosteroids,potentanti-inflammatoryagents,aretheoreticallyexpectedtoberelevant treatmentforARDS.Inpractice,clinicaltrialsfoundvariablyfavorable,neutralorharmful effectsofcorticosteroidsinARDS. InanancillaryanalysisofaRCTfocusedonsepticshock,Annaneetal.,foundthat 7-day treatment with low dose of steroids was significantly associated with better out- comesinsepticshockassociatedwithearlysepticARDSinnon-responderstoshortcosyn- tropinstimulationtest[47]. Inatrialof24ARDSpatients,earlycorticosteroidtreatment (methylprednisolone2mg/kg/dfollowedbyprogressivedosetaperingover32days]was associatedwithasignificantreductioninlunginjuryscore(LIS)(p<0.003at5days)[60]. Similarfindingswereobservedinalargercohort(LIS69.8%inplacebogroupvs. 35.7% incorticosteroidsgroup; p=0.02),withmethylprednisolone1mg/kg/d(progressively taperedoffover28days)[61]. InanEgyptianstudy,earlyadministrationofhydrocortisone insepticARDSwasassociatedwithimprovedoxygenationparametersandLISwithout achievingasurvivalbenefitonday28[62]. Trialofshortcourseofhighdosecorticosteroids (vs. placebo]foundnoevidenceforimproved45-daymortalityinadultswithARDS(60% vs. 63% p = 0.74) [63]. More recently, Villar et al., found that in ARDS, dexamethasone (20mgIVdailybetweenday1to5,then10mgdailybetweenday6to10)comparedto placebo,increasedthenumberofventilator-freedays(between-groupdifference4.8days [95%CI2.57to7.03];p<0.0001),andreducedmortalityatday60(between-groupdifference −15.3%[−25.9to−4.9];p=0.0047)[64]. 2.2. CorticosteroidsinLate-StageARDS Late-stageARDSischaracterizedhistologicallybyongoinginflammationwithfibro- proliferation, presence of hyaline membranes, and persistent diffuse alveolar damage, leadingtoprolongedmechanicalventilationandahigherriskofdeath[21]. Medurietal., reportedin9ARDSpatientswithpulmonaryfibrosis,thathighdoseofmethylprednisolone mayimprovetheLIS[65]. Wajanaponsanetal.,foundthatlowdosemethylprednisolone administered>14daysafteronsetofARDSwasassociatedwithincreasedmortalityrates at60and180days[66]. Thelargestmulticenterplacebo-controlledtrial,foundnoevidence fordifferencein60-daymortalitywithcorticosteroidsinitiatedforlate-stageARDS(36% vs. 27%p=0.26)[67]. 2.3. DoseandTypeofCorticosteroid Notallcorticosteroidsexhibitthesamebiologicalproperties. Thedoseandtypeof corticosteroidmayyieldvariableeffectsonpatients’outcomes. Inatrialof304patients withsepsis,highdosesofmethylprednisoloneledtonumericallymorepatientswithARDS incorticosteroidsvs. placebo(32%vs. 25%p=0.1),fewerreversionsofARDS(31%vs. 61% p=0.015),andahigher14-daymortality(52%vs. 22%p=0.04)[68]. InanotherARDS trial, high doses of methylprednisolone [30 mg/kg every 6 h for 1 day] did not reduce mortality(p=0.74)orreverseARDS(p=0.77)[63]. InanothertrialinpatientswithARDS andcriticalillnessrelatedcorticosteroidsinsufficiency,hydrocortisoneadministered3times aday(1mg/kg/d)forsevendaysincreasedsurvivalratesandreducedshockrate(5/12 vs. 10/14,p<0.05),withnosignificanteffecton28-daymortality[69]. J.Clin.Med.2023,12,3340 5of16 2.4. Pathogens TheuseofcorticosteroidsinviralARDS,especiallyininfluenzarelatedARDS,remains controversial[70].Inaretrospectivestudy,earlycourseofcorticosteroidsmaybeassociated with increased mortality risk (33.7% vs. 16.8%, p = 0.005) [71]. Worst outcomes with corticosteroidsininfluenzarelatedARDSmayberelatedtothedegreeofviralreplication, ortobacterialco-infections. Similarly,anotherobservationalstudyfoundincreasedICU mortality with corticosteroids (27.5% vs. 18.8%, p < 0.001) [72]. Observational studies insevereSARSandMERSinfections,corticosteroidswerenotassociatedwithimproved outcomes[73–76]. Theseobservationalstudieshavehighlikelihoodofselectionbiaswith corticosteroidsbeinggiventothesickestpatients[77]. Relyingonindirectevidencefrom observational studies in flu, SRAS and MERS infections, initial recommendations were againstadministeringcorticosteroidsinSARS-CoV-2[78]. PatientssufferingfromCOVID-19exhibitelevatedlevelsofinflammatorycytokines and chemokines, similarly to sepsis [79]. Corticosteroids were the first treatment to be effectiveinreducingmortalityinoxygendependentSARS-CoV-2relatedacuterespiratory failure [80]. Although studies of corticosteroids in COVID-19 acute respiratory failure didnotusetheBerlindefinitionofARDS,theirbiological,clinicalfeaturesandoutcomes are highly similar [81]. RECOVERY was the first trial (n = 6245 patients enrolled) to demonstratethesurvivalbenefitsfromdexamethasoneinCOVID-19. Amonghospitalized patients, dexamethasone 6 mg for up to 10 days resulted in a lower 28-day mortality comparedtousualcare,especiallyinpatientswhowerereceivingmechanicalventilation (29.3% vs. 41.4%; RR 0.64; 95% CI [0.51 to 0.81]) [82]. These results were subsequently confirmed by several other trials [83–86] [Table 2], and a large meta-analysis of 7 trials accountingfor1703patients(RRfor28-daymortality0.7995%CI[0.70to0.90])[80]. Subsequent studies sought to determine whether higher doses of corticosteroids were more efficient in COVID-19. Munch et al., found that dexamethasone 12 mg/d did not improve the number of days alive without life support compared to standard doses(dexamethasone6mg/J)(adjustedmeandifference,1.3days[95%CI,0to2.6days]; p =0.07)[87]. Bouadmaetal., inCOVIDICUSobtainedsimilarresults, higherdosesof dexamethasone (20 mg/d for 10 d) did not significantly improve mortality compared to a standard dose (HR, 0.96 [95% CI, 0.69 to 1.33]; (p = 0.79)) [88]. Current guidelines recommendadministratingdexamethasone6mgperdayfor10daysinsevereCOVID- 19[89]. 2.5. AdverseEvents Theadministrationofcorticosteroidsmaybeassociatedwithadverseevents. Inhigh- qualitytrialsandmeta-analysesinsepsisandinARDS,indicatethemainadverseevents associated with corticosteroids may include neuromuscular weakness, gastrointestinal bleeding,hypernatremiaandhyperglycemia[52,90]. Ameta-analysisof18trialsincluding 2826ARDSpatients,foundnoevidenceforincreasedriskofmuscularweakness: RR0.85 95%CI[0.62to1.18]orgastrointestinalbleedingRR1.2095%CI[0.43to3.34],butincreased riskofhyperglycemiaRR1.1195%CI[1.01to1.23]. J.Clin.Med.2023,12,3340 6of16 Table1.CorticosteroidsforearlyARDS. Author,Reference Type SampleSize StudyPopulation Treatment Results ARDSas Partialpressureofoxygen≤70 PEPmortality mmHgon>40%oxygen, MPS30mg/kgIV6hourlyfor24h Bernardetal.[63] RCT,multicenter 99 MPS30/50(60%);Pl31/49(63.2) PaO /PAO ratio<0.3,bilateral vs.placebo 2 2 OR0.75[0.4to1.57]p=0.74 lunginfiltrates,pulmonaryartery wedgepressure≤18mmHg PEPLunginjuryandmortalityday10 MPSLoadingdoseof2mg/kg; ARDS1994 MPS1.7[0.1];Pl3.0[0.2];p<0.001 then2mg/kg/dfromday1today 7daysofmechanicalventilation SEP: 14,1mg/kg/dfromday15today21, RCT withanLISof2.5orgreaterand Mortality Medurietal.[60] 24 0.5mg/kg/dfromday22today28, multicenter lessthana1-pointreductionfrom MPS0/16(0%);Pl5/8(62%)p=0.002 0.25mg/kg/dondays29and30, day1ofARDS,andnoevidenceof Mortalityinhospital 0.125mg/kg/dondays31and32. untreatedinfection. MPS2/16(12.5%);Pl5/8(62.5%) vs.placebo OR0.41[0.06to99]p=0.03 MPSLoadingdoseof2mg/kgof ARDS1994inearlyandlatestage predictedbodyweightfollowedby InearlyARDS(7–13d) Steinbergetal., RCT Atleast7daysdurationARDS;p/F 132/180 0.5mg/kg6hourlyfor14days;0.5 PEPmortalityat60days ARDSnetwork,[67] Multicenter <200 mg/kg12hourlyfor7days;and MPS(36%);Pl(27%)p=0.26 Intubated,mechanicalventilation thentaperingofthedose. PEP:mortalityat28-day Inthenon-respondersubgroup ARDS1994bilateralinfiltrateon 129/300 HSHC+FC33/62(53%);Pl50/67(75%) chestradiography,PaO /FiO < 177ARDS: 2 2 HSHC50mgIV6hourlyand RR=0.71;95%CI[0.54to0.94]p=0.013 200mmHgandPulmonary Annaneetal.[47] postHocRCT 129non 9-alphafludrocortisoneonceaday OR=0.35;95%CI[0.15to0.82],p=0.016). occlusionpressure≤18mmHgor responders,48 for7days. IntherespondergroupNosignificantresult noclinicalevidenceofleftatrial responder HSHC+FC16/23(70%);PL12/25(48%) hypertension RR=1.4;95%CI[0.89to2.36]p=0.130 OR=2.29;95%CI[0.49to10.64]p=0.290 MPSLoadingdoseof1mg/kg Then1mg/kg/dfromday1today PEP1-pointreductioninLISor ARDS1994Intubatedand 14,0.5mg/kg/dfromday15today MPS69.8%vs.Pl35.7%;p=0.002 Medurietal.[61] RCTmulticenter 91 MechanicalventilationARDS≤72 21,0.25mg/kg/dfromday22today successfulextubation7-day Hofstudyentry 25,0.125mg/kg/dfromday26to MPS53.9%vs.Pl25.0%;p=0.01 day28. J.Clin.Med.2023,12,3340 7of16 Table1.Cont. Author,Reference Type SampleSize StudyPopulation Treatment Results Severesepsisorsepticshock receivingIMVforhypoxemic PEP28dayall-causemortality RCT respiratoryfailurewithin12Hof HSHC(22.5%)vs.Pl(27.3%)RR0.82[0.50to Tongyooetal.[91] 197 HSHC50mgevery6horplacebo Singlecenter studyentry+ARDS1994then 1.34]p=0.51 reclassifiedaccordinglytoARDS HR0.80,95%CI[0.46to1.41];p=0.44 2012 PEPN◦ventilator-freefromdayof 277/314 ARDS2012(butPEEP≥10) Villaretal., RCT DXMIV20mgoncedailyday1to5 randomizationtoday28 stoppedlow ModeratetosevereARDS<24h DEXA-ARDS,[64] multicenter then10mgoncedailyday6to10 Between-groupdifference4.8days95%CI[2.57 enrollment88% (butPEEP≥10) to7.03];p<0.0001). PEP28dmortality Overall:DXM482/2104(22.9%);Pl1110/4321 Hospitalizedpatientswith Horbyetal., DXM6mg(IVororally)during10 (25.7%)(age-adjustedRR0.83;95%CI[0.75to RCTmulticenter 6425 suspectedorlaboratoryconfirmed RECOVERY,[82] daysvs.usualcare 0.93];p<0.001) COVID-19 >subgroupmechanicalventilation(1007):29.3% vs.41.4%;RR0.64;95%CI[0.51to0.81] COVID-19infectionsuspectedor PEPVentilator-freedays(alive+freefromIMV) Tomazinietal., confirmed,receivingIMVwithin DXM20mgdailyfor5days DXM6.695%CI[5.0to8.2)vs.Pl4.095%CI[2.9 RCTmulticenter 299/350 CoDEX,[84] 48Hofmeetingcriteriafor followedby10mgdailyfor5days to5.4] moderatetosevereARDS2012 difference4.095%CI[2.9to5.4] PEP:21-daytreatmentfailure(deathor Confirmedorsuspected HSHC200mgdailyfor4to7then persistentdependencyonmechanical SARS-CoV-2+1severitycriteria Dequinetal.,CAPE RCT 100mgdailyfor2to4days ventilationorhigh-flowoxygentherapy 149/290 IMV(PEEP>5cmH O),p/F<300 COVID[92] multicenter 2 then50mgdailyfor2to3days HSHC42.1%vs.pl50.7% HFOT>50%Fi,PaO /FiO <300 2 2 total8days Difference−8.6%[95.48%CI,−24.9%to7.7%]; FMOT(specifiedcharts),PSI>130 p=0.29) COVID-19suspectedorconfirmed, 3randomizationarms severe PEPCompositeofhospitalmortalityandICU Fixed:HSHC50mgevery6hdaily ICUfor organsupport-freedaystoday21 for7days Angusetal., Respiratoryfailure(invasiveor Fixed0QR,−1to15;OR1.4395%CI[0.91to RCTmulticenter 384 Shock:HSHC50mg/6hfor7days REMAPCAP-[85] non-invasiveIMVorHFNflow 2.27] whileinshock rate>30L/m,andFI>40% Shock0IQR,–1to13;OR1.2295%CI[0.76–1.94] NoHSHC Cardiovascularfailure: None00(IQR,−1to11) Or200mg/6hfor7days vaopressor/inotrope J.Clin.Med.2023,12,3340 8of16 Table1.Cont. Author,Reference Type SampleSize StudyPopulation Treatment Results PEPpulmonaryfunctiontestingatday120 Clinical-radiologicalsuspicionof follow-upvisit.(Pulmonaryfunctionand Barrosetal., COVID-19 MPSIV0.5mg/kgevery12h×5 maximalrespiratorypressuretesting,DASI, RCTsinglecenter 246 MetCOVID[86] Sat≤94%inroomairorRequiring days 6MWT) O orIMV FEV1(2.6,[0.7],p=0.01)andFVC(3.2,[0.8], 2 p=0.01 Severecommunity-acquired pneumoniae,definedbythe presenceofatleastoneoffour followingcriteria TheinitiationofMV(invasiveor noninvasive)withapositive end-expiratorypressurelevel≥ 5cmofwater Theinitiationoftheadministration HSHCcontinuousIV200mg/day PEPmortalityatday28 ofoxygenthroughaHFOTwitha duringthefirst4days. HSHC25of400patients6.2%;95%CI,[3.9to Dequinetal., ratioofPaO :FiO <300,witha Onday4,regardingmedicaldecision 8.6]vs.placebo47of395patients11.9%;95%CI, RCTmulticenter 795 2 2 CAPECOD,[54] FiO of50%ormore; basedonpredefinedcriteria, [8.7to15.1] 2 Forpatientswearinga followingadministrationforatotal (Absolutedifference,−5.6percentagepoints; non-rebreathingmask,an of8or14days 95%CI,[−9.6to−1.7];p=0.006). estimatedPaO :FiO ratio<300,or 2 2 ascoreofmorethan130onthe PulmonarySeverityIndex,which classifiespatientswith community-acquiredpneumonia intofivegroupsaccordingto increasingseverity,withascoreof morethan130defininggroupV PEP:primaryendpoint;SEP:secondaryendpoint;MPS:Methylprednisolone;HSHC:hemisuccinatehydrocortisone;DXM:dexamethasoneARDS:acuterespiratorydistresssyndrome; AHRF:acutehypoxemicrespiratoryfailure,IMV:invasivemechanicalventilation;LIS:lunginjuryscore;HFOT=Highflowoxygentherapy;FMOT:facemaxoxygentherapy; PaO2/FiO2:partialpressureofoxygen/fractionofinspiredoxygen;ARDSAEEC1994:acutesyndrome,hypoxemiaPaO2/FiO2<200,bilateralinfiltrateonchestradiography,cannotbe duetocardiacfailure[elevatedleftatrialpressure]assessedbyclinicalexaminationoraPCWP>18cmH2O;ARDSBerlin2012:≤7dayssinceonsetofpredisposingclinicaldefinition, bilateralopacitiesonX-rayorCTscannoattributedtopleuraleffusion,atelectasisornodules,respiratoryfailurethatcannotbeattributedtoheartfailureorvolumeoverload,PaO2/FiO2 withuseof≥5cmH2OofPEEP([201–300mmHg]asmildARDS;[101–200mmHg]asmoderateARDS;<100mmHgassevereARDS)andperformadditionalstudiestoruleout cardiogenicoedema(echocardiography,BNP). J.Clin.Med.2023,12,3340 9of16 Table2.DoseeffectinsepticARDSandSARS-CoV-2Acuterespiratoryfailure—RCT. Author, Dose Type SampleSize StudyPopulation Treatment Results Reference PEP:ARDSdevelopment Sepsisdefineas feverorhypothermiarectalT◦>38.3 MPS50/15232% or<35.5◦C Pl:38/15225%(p=0.1) SEP: tachypnea(>20bpm),tachycardia RCT 382(304 MPS,30mg/kg,everysixhours ReverseARDS Boneetal.[68] (>90bpm) multicenter randomized) for48hvs.placebo MPS15/50(31%);Pl:23/38(61%) oneofthefollowingindicesoforgan (p=0.005) dysfunction:achangeinmentalstatus, 14dmortality hypoxemia,elevatedlactatelevelsor HighDose MPS26/50(52%);Pl8/22(%) oliguria (p=0.004) PEPmortality ARDSPartialpressureofoxygen≤70 MPS30/50(60%);Pl31/49(63.2) RCT mmHgon>40%oxygen,PaO2/PAO2 MPS30mg/kgIV6hourlyfor24 OR0.75[0.4to1.57]p=0.74 Bernardetal.[63] 99 ratio<0.3,bilaterallunginfiltrates, multicenter hvs.placebo SEP pulmonaryarterywedgepressure≤18 reversalofARDS mmHg MPS18/50(39%);Pl19/49(36%)(p=0.07) PEPVentilator-freedays(alive+freefromIMV) DXM6.695%CI%[5.0to8.2]vs.Pl4.095%CI[2.9 Tomazinietal., COVID-19moderatetosevereARDS RCT DXM20mgdailyfor5days to5.4] CoDEX, 299/350 accordingtoBerlin,mechanical multicenter followedby10mgdailyfor5days difference4.095%CI[2.9to5.4] [84] ventilation SEP 28dmortalityallcausenodifference PEPpulmonaryfunctiontestingatday120 follow-upvisit.(pulmonaryfunctionandmaximal Barrosetal., RCTsingle InhospitalCOVID-19 MPSIV0.5mg/kgevery12h×5 246 respiratorypressuretesting,DASI,6MWT) MetCOVID,[86] center RequiringO2orIMV days FEV1(2.6,[0.7],p=0.01)andFVC(3.2,[0.8], High- p=0.01 ModerateDose PEPnumberofdaysalivewithoutlifesupportat Munchetal., RCT ConfirmedCOVID-19with>10L/mn DXM12mg/dvs.DXM6mg/d 28d COVIDSTEROID, 982/1000 [87] multicenter O2orIMV for10days 22dvs.20.5dadjustedmeandifference,1.3days 95%CI[0to2.6days];p = 0.07 AdmittedtoICUwithin48Hfor DXM6mg/dfor10days(or confirmedorhighlysuspected placebopriortoRECOVERY PEPday60all-causemortality Bouadmaetal., COVID-19 RCT resultcommunication)or Low26.8%vs.High25.9% COVIDICUS, multicenter 546 AHRF(PaO2<70mmHg,SpO2< Dexamethasone20mg/dfor5 Absoluteriskdifference−0.8%95%CI[−8.3to6.5] [88] 90%,tachypnea>30mn,labored daysfollowedbyDexamethasone HR,0.9695%CI[0.69to1.33];(p=0.79) breathing,respiratorydistress,orneed 10mg/dfor5days ofO2flow≥6L/mn) J.Clin.Med.2023,12,3340 10of16 Table2.Cont. Author, Dose Type SampleSize StudyPopulation Treatment Results Reference PEP:21-daytreatmentfailure(deathorpersistent dependencyonmechanicalventilationor ConfirmedorsuspectedSARS-CoV-2+ high-flowoxygentherapy 1severitycriteria HSHC42.1%vs.pl50.7% HSHC200mgdailyfor4to7then Dequinetal., RCT IMV(PEEP>5cmH2O),p/F<300 100mgdailyfor2to4days Difference−8.6%95.48%CI[−24.9%to7.7%]; CAPECOVID, multicenter 149/290 HFOT>50%Fi,PaO2/FiO2<300 then50mgdailyfor2to3days p=0.29) [92] FMOT(specifiedcharts),PSI>130 SEP total8days Excludedsepticshock 21dmortality Lowrecruitment HSHC14.7%vs.placebo27.4% difference−12.7%95%CI[−25.7%to0.3%]; p=0.06 PEPCompositeofhospitalmortalityandICU COVID-19suspectedorconfirmed, organsupport-freedaystoday21 severe 3randomizationarms Fixed0QR,−1to15;OR1.4395%CI[0.91to2.27] ICUfor Fixed:HSHC50mgevery6h LowDose Shock0IQR,−1to13;OR1.2295%CI[0.76to1.94] Angusetal., Respiratoryfailure(invasive)or dailyfor7days RCT None00(IQR,−1to11) REMAPCAP, 384 noninvasiveMVorHFNflowrate> Shock:HSHC50mg/6hfor7 multicenter SEP [85] 30L/m,andFI>40% dayswhileinshock 28dmortality Cardiovascularfailure: NoHSHC Fixed30%;OR1.0395%CI[0.53to1.95] vasopressor/inotrope Or200mg/6hfor7days Shock26%;1.1095%CI[0.58to2.11] Stopethical None33% PEP28dmortality Overall:DXM482/2104(22.9%);Pl1110/4321 (25.7%)(age-adjustedRR0.83;95%CI[0.75to0.93]; p<0.001) Horbyetal., RCT hospitalizedpatientswithsuspected DXM6mg(IVororally)for10 6425 >subgroupmechanicalventilation(1007):29.3%vs. RECOVERY,[82] multicenter orlaboratoryconfirmedCOVID-19 daysvs.usualcare 41.4%;RR0.64;95%CI[0.51to0.81) SEP Invasivemechanicalventilationordeath RR0.93;95%CI[0.85to1.01] J.Clin.Med.2023,12,3340 11of16 Table2.Cont. Author, Dose Type SampleSize StudyPopulation Treatment Results Reference Symptom>7days Radiologicalevidenceoflungdisease onchestX-rayorCT-scan Moderatetoseverediseasewith abnormalgasexchange: PEP:Compositeendpoint(in-hospitalall-cause Corral-Gudino (PaO2/FiO2orPaFi)<300 mortality,escalationtoICUadmission,or etal., RCT 64/180 Or(SaO2/FiO2orSaFi)<400 MPS40mgIVq12×3daysand progressionofrespiratoryinsufficiencythat GLUCOCOVID, multicenter Lowrecruitment Or≥2criteriaoftheBRESCIA-COVID then20mgq12h×3days requirednoninvasiveventilation) [93] RespiratorySeverityScale(BCRSS InITT:MPS40%vs.Pl48%p=0.25 Evidenceofasystemicinflammatory InPP:RR0.4295%CI[0.20to0.89] response:serumC-reactiveprotein> 15mg/dL,D-dimer>800ng/mL, ferritin>1000mg/dL,orIL-6levels> 20pg/mL PEP:primaryendpoint;SEP:secondaryendpoint;MPS:Methylprednisolone;HSHC:hemisuccinatehydrocortisone;DXM:dexamethasoneARDS:acuterespiratorydistresssyndrome; AHRF:acutehypoxemicrespiratoryfailure,IMV:invasivemechanicalventilation;LIS:lunginjuryscore;HFOT=Highflowoxygentherapy;FMOT:facemaxoxygentherapy; PaO2/FiO2:partialpressureofoxygen/fractionofinspiredoxygen;ARDSAEEC1994:acutesyndrome,hypoxemiaPaO2/FiO2<200,bilateralinfiltrateonchestradiography,cannotbe duetocardiacfailure(elevatedleftatrialpressure)assessedbyclinicalexaminationoraPCWP>18cmH2O;ARDSBerlin2012:≤7dayssinceonsetofpredisposingclinicaldefinition, bilateralopacitiesonX-rayorCTscannoattributedtopleuraleffusion,atelectasisornodules,respiratoryfailurethatcannotbeattributedtoheartfailureorvolumeoverload,PaO2/FiO2 withuseof≥5cmH2OofPEEP([201–300mmHg]asmildARDS;[101–200mmHg]asmoderateARDS;<100mmHgassevereARDS)andperformadditionalstudiestoruleout cardiogenicoedema(echocardiography,BNP). J.Clin.Med.2023,12,3340 12of16 3. Summary MultiplestudieshaveyieldedvariableeffectsofcorticosteroidsinARDS.Discrepan- ciesbetweenstudiesmaybeexplainedbymultiplefactorssuchasdifferencesinstudy design,causesofARDS,dose,timingofinitiation,duration,modalitiesoftreatmentcessa- tion,andtypeofcorticosteroids. DespitedecadesofcontroversiesabouttheuseofcorticosteroidsinARDS,thedemon- strationthatcorticosteroidssavednumerouslivesduringtheCOVIDpandemicrenewed theinterestininvestigatingthebenefit-to-riskbalanceofcorticosteroidsinARDS.Like- wise,therecentcharacterizationofARDSphenotypesandendotypesdelineatestreatable traitspossiblyrelevanttocorticotherapy[94]. Alveolarprocollagenmaybeanindicatorof fibroproliferation,whichmayhelpidentifynon-resolvingARDSthatislikelytorespondto treatmentbycorticosteroids[95]. TheanalysisofexpiredairinARDSisalsoapromising venueofresearch[96]. 4. Conclusions Corticosteroidsareeffectivetreatmentforseverecommunity-acquiredpneumonia, septicshockandCOVID-19-relatedacuterespiratoryfailure.High-qualitytrialsareawaited beforeabroaderuseofcorticosteroidsinARDS. AuthorContributions:Allauthorsparticipatedinwritingtheoriginaldraft.Allauthorshaveread andagreedtothepublishedversionofthemanuscript. Funding: Thisarticlewassupportedbypublicgrants“Programmed’Investissementsd’Avenir” (PIA),referenceANR-18-RHUS-0004,andERAPerMed,JCT2021. InstitutionalReviewBoardStatement:Notapplicable. InformedConsentStatement:Notapplicable. DataAvailabilityStatement:Nonewdatawerecreatedoranalyzedinthisstudy.Datasharingis notapplicabletothisarticle. ConflictsofInterest:Theauthorsdeclarenoconflictofinterest. References 1. Singer,M.;Deutschman,C.S.;Seymour,C.W.;Shankar-Hari,M.;Annane,D.;Bauer,M.;Bellomo,R.;Bernard,G.R.;Chiche,J.-D.; Coopersmith,C.M.;etal.TheThirdInternationalConsensusDefinitionsforSepsisandSepticShock(Sepsis-3).JAMA2016,315, 801–810.[CrossRef][PubMed] 2. Stearns-Kurosawa,D.J.;Osuchowski,M.F.;Valentine,C.;Kurosawa,S.;Remick,D.G.ThePathogenesisofSepsis. Annu. Rev. Pathol.2011,6,19–48.[CrossRef][PubMed] 3. Fleischmann,C.;Scherag,A.;Adhikari,N.K.J.;Hartog,C.S.;Tsaganos,T.;Schlattmann,P.;Angus,D.C.;Reinhart,K.Assessment ofGlobalIncidenceandMortalityofHospital-treatedSepsis.CurrentEstimatesandLimitations.Am.J.Respir.Crit.CareMed. 2016,193,259–272.[CrossRef][PubMed] 4. Fleischmann-Struzek,C.;Mellhammar,L.;Rose,N.;Cassini,A.;Rudd,K.E.;Schlattmann,P.;Allegranzi,B.;Reinhart,K.Incidence andmortalityofhospital-andICU-treatedsepsis:Resultsfromanupdatedandexpandedsystematicreviewandmeta-analysis. IntensiveCareMed.2020,46,1552–1562.[CrossRef] 5. Rudd,K.E.;Johnson,S.C.;Agesa,K.M.;Shackelford,K.A.;Tsoi,D.;Kievlan,D.R.;Colombara,D.V.;Ikuta,K.S.;Kissoon,N.;Finfer, S.;etal.Global,regional,andnationalsepsisincidenceandmortality,1990–2017:AnalysisfortheGlobalBurdenofDiseaseStudy. Lancet2020,395,200–211.[CrossRef] 6. Reinhart,K.RecognizingSepsisasaGlobalHealthPriority—AWHOResolution|NEJM.Availableonline:https://www.nejm. org/doi/full/10.1056/nejmp1707170(accessedon2January2023). 7. Torio,C.M.;Andrews,R.M.NationalInpatientHospitalCosts:TheMostExpensiveConditionsbyPayer,2011.InHealthcareCost andUtilizationProject(HCUP)StatisticalBriefs;AgencyforHealthcareResearchandQuality:Rockville,MD,USA,2006.Available online:http://www.ncbi.nlm.nih.gov/books/NBK169005/(accessedon2January2023). 8. Annane,D.;Sharshar,T.Cognitivedeclineaftersepsis.LancetRespir.Med.2015,3,61–69.[CrossRef] 9. Annane,D.;Pastores,S.M.;Rochwerg,B.;Arlt,W.;Balk,R.A.;Beishuizen,A.;Briegel,J.;Carcillo,J.;Christ-Crain,M.;Cooper, M.S.;etal. GuidelinesfortheDiagnosisandManagementofCriticalIllness-RelatedCorticosteroidInsufficiency(CIRCI)in CriticallyIllPatients(PartI):SocietyofCriticalCareMedicine(SCCM)andEuropeanSocietyofIntensiveCareMedicine(ESICM) 2017.Crit.CareMed.2017,45,2078–2088.[CrossRef]",
    "Conclusion": ""
  },
  "meta": {
    "findit_url": "http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10179626&blobtype=pdf"
  }
}